Switch to:

# Denali Therapeutics ROC %

: -416.08% (As of Sep. 2019)
View and export this data going back to 2017. Start your Free Trial

Return on capital measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Denali Therapeutics's annualized return on capital (ROC) for the quarter that ended in Sep. 2019 was -416.08%.

As of today (2020-01-17), Denali Therapeutics's WACC % is 0.00%. Denali Therapeutics's return on capital is -109.08% (calculated using TTM income statement data). Denali Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

## Denali Therapeutics ROC % Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

 Denali Therapeutics Annual Data Dec15 Dec16 Dec17 Dec18 ROC % 0.00 0.00 0.00 -65.26

 Denali Therapeutics Quarterly Data Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 ROC % -148.95 354.20 -183.69 -293.69 -416.08

## Denali Therapeutics ROC % Calculation

Denali Therapeutics's annualized Return on Capital (ROC) for the fiscal year that ended in Dec. 2018 is calculated as:

 Return on Capital (ROC) (A: Dec. 2018 ) = NOPAT / Average Invested Capital = Operating Income*(1-Tax Rate) / ( (Invested Capital (A: Dec. 2017 ) + Invested Capital (A: Dec. 2018 )) /2) = -46.372 * ( 1 - 0% ) / ( (59.57 + 82.548) /2) = -46.372 / 71.059 = -65.26 %

 Invested Capital (A: Dec. 2017 ) = Book Value of Debt + Book Value of Equity - Cash = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Minority Interest + Total Stockholders Equity - Cash = 0 + 0 + 0 + 465.796 - 406.226 = 59.57

 Invested Capital (A: Dec. 2018 ) = Book Value of Debt + Book Value of Equity - Cash = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Minority Interest + Total Stockholders Equity - Cash = 0 + 0 + 0 + 546.845 - 464.297 = 82.548

Denali Therapeutics's annualized Return on Capital (ROC) for the quarter that ended in Sep. 2019 is calculated as:

 Return on Capital (ROC) (Q: Sep. 2019 ) = NOPAT / Average Invested Capital = Operating Income*(1-Tax Rate) / ( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 )) /2) = -200.62 * ( 1 - 0.24% ) / ( (67.481 + 28.722) /2) = -200.138512 / 48.1015 = -416.08 %

where

 Invested Capital (Q: {Q2}) = Book Value of Debt + Book Value of Equity - Cash = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Minority Interest + Total Stockholders Equity - Cash = 70.911 + 0 + 0 + 475.173 - 478.603 = 67.481

 Invested Capital (Q: Sep. 2019 ) = Book Value of Debt + Book Value of Equity - Cash = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Minority Interest + Total Stockholders Equity - Cash = 69.915 + 0 + 0 + 438.197 - 479.39 = 28.722

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Denali Therapeutics  (NAS:DNLI) ROC % Explanation

Return on Capital measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is Return on Capital important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Denali Therapeutics's WACC % is 0.00%. Denali Therapeutics's return on capital is {stock_data.stock.roic}}% (calculated using TTM income statement data). Denali Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE and ROA, ROC is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

## Denali Therapeutics ROC % Headlines

From the Internet

###### Novavax Rises on Fast Track Designation to Influenza Vaccine

- Zacks 2020-01-16 08:52:00

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to \$400 per referral. ( Learn More)
/* */